GeneDx Holdings Corp. last reported quarterly results on Aug 3, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $114.4 million (+11.4% year over year) and diluted EPS of -$0.60. It usually reports 12–34 days after a quarter ends. Based on that pattern, the next release is estimated for around Oct 27, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Oct 28, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–34 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
114
+11.4%
|
-18
-264.1%
|
-0.60
-266.7%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
102
+17.4%
|
-63
-869.8%
|
-2.16
-839.1%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
121
+26.5%
|
-18
-424.9%
|
-0.61
-410.7%
|
|
Oct 28, 2025
28 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
117
+51.9%
|
-8
+8.1%
|
-0.27
+12.9%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
103
+45.6%
|
11
+137.1%
|
0.36
+132.7%
|
|
Apr 30, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
87
+39.6%
|
-7
+67.7%
|
-0.23
+70.5%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
96
+66.6%
|
5
+121.1%
|
0.20
+119.7%
|
|
Oct 29, 2024
29 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
77
+44.2%
|
-8
+80.3%
|
-0.31
+81.1%
|
Company profile
- Industry
- Services-Health Services (SIC 8000)
- Listed as
- WGS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Stamford, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1818331
- Former names
- Sema4 Holdings Corp. (until Jan 5, 2023); CM Life Sciences, Inc. (until Jul 21, 2021)
Other Services-Health Services companies
- LifeStance Health Group, Inc. LFST
- Privia Health Group, Inc. PRVA
- Pennant Group, Inc. PNTG
- U S Physical Therapy Inc /NV USPH
- InnovAge Holding Corp. INNV
- Omada Health, Inc. OMDA
- P3 Health Partners Inc. PIII
- Alps Group Inc ALPS
Source: SEC EDGAR filings. This is company-reported data, not investment advice.